+1 (888) 794-0077
« Return

Ensure a Successful Clinical Translation with DMPK Strategies

DMPK – A Key Step, Every Step of the Way

Drug metabolism and pharmacokinetics (DMPK) is a crucial component in the success of your drug development – at every stage, from discovery to preclinical to clinical.

DMPK studies set basic expectations of drug behavior, which is necessary in order to move your current or upcoming project to first-in-human trials. Tune in to this webinar to get information and strategies to help you more quickly and efficiently do just that.

What You’ll Learn

In this webinar, Dr. Jing Jin*, head of WuXi AppTec’s DMPK Study Director team, discusses the DMPK screening roadmap, considerations when moving into clinical stages, strategies for the development of novel therapeutics, and what a successful IND application should include – with tips on what regulatory agencies may look for in future applications.

These topics will include the specifics of:

  • Desired dose regimen (dose level and frequency)
  • Balanced disposition pathways
  • No human-specific metabolites
  • Low drug-drug interaction potential
  • Minimal risk of forming reactive metabolites

Move your project forward faster.

*Dr. Jin Jing leads the DMPK Study Director Team at WuXi AppTec’s Shanghai, China location. With more than a decade of experience, Dr. Jin has applied his expertise in drug metabolism and pharmacokinetics at WuXi AppTec since 2016. Before joining the company, he was an investigator of Clinical Pharmacology at Novartis. Dr. Jin provides a wealth of knowledge about the DMPK drug development journey – from discovery to clinical, and is a frequent speaker on the subject. He received his B.S. in Biochemistry from Nanjing University and his Ph.D. in Pharmacology from Vanderbilt University.

For more information, please visit: https://labtesting.wuxiapptec.com/


As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and life sciences industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received an AA ESG rating from MSCI for the fourth consecutive year in 2024 and its open-access platform is enabling around 6,000 customers from over 30 countries to improve the health of those in need – and to realize the vision that “every drug can be made and every disease can be treated.”

Related Posts

From Bottlenecks to Breakthroughs: 5 Ways Automation Transforms Toxicology Scheduling

From Bottlenecks to Breakthroughs: 5 Ways Automation Transforms Toxicology Scheduling

Traditional toxicology testing requires complex schedules that align task workflows with finite resources such as technician time and access to laboratories and equipment. Managing interdependent parts of the process manually with spreadsheets or other basic tools, while easily accessible, is inflexible, cumbersome, and prone to error and inefficiency . Automated platforms and workflow systems have the potential to optimize—or revolutionize—all aspects of drug development and testing to enhance speed, accuracy, and coordination.

3 Therapeutic Considerations for the Future of Oligonucleotide Development

3 Therapeutic Considerations for the Future of Oligonucleotide Development

Oligonucleotide-based therapies are redefining how we approach diseases at their genetic origins. By modulating gene expression at the RNA level, these therapies offer an unprecedented degree of precision in drug development, making once-untreatable diseases targets for real solutions. This guide explores the therapeutic opportunities and innovations shaping oligonucleotide development and what it could mean for the future of patient care.